Skip to main content
Article thumbnail
Location of Repository

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential

By Michael Rud Lassen and Volker Laux

Abstract

In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder, with hospital admission rates that appear to be increasing. Current anticoagulant therapies available for the prevention and treatment of VTE have several drawbacks that make them either difficult to manage effectively, due to a need for careful monitoring to control coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. To address some of these issues, new anticoagulants are in clinical development that can be orally administered and directly target specific factors in the coagulation cascade. This article reviews the rationale behind development of these novel agents and provides a critical appraisal of their clinical potential. In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2663445
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
    2. (2008). A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study.
    3. (2006). A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (the RE-MODEL trial).
    4. (2005). A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
    5. (2006). A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939., for thromboprophylaxis after total hip replacement.
    6. (2003). A phase II randomized, double-blind, fi ve-arm, parallel-group, dose-response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention or deep vein thrombosis in knee replacement surgery. Blood,
    7. (2007). A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
    8. (2005). A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.
    9. A randomized, double-blind study.
    10. (1992). Aging and the anticoagulant response to warfarin therapy.
    11. (2005). An oral, direct Factor Xa inhibitor – BAY 59–7939 – for prophylaxis against venous thromboembolism after total knee replacement: a phase II dose-ranging study.
    12. (2006). Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral Factor Xa inhibitor. Blood, 108:Abstract 901.
    13. (2007). Anticoagulation treatment for the reduction of stroke in atrial fi brillation: a cohort study to examine the gap between guidelines and routine medical practice.
    14. (2007). Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo fl ow chamber. Thromb Haemost,
    15. (2004). Antithrombotic therapy for venous thromboembolic disease:
    16. (2007). Beyond unfractionated heparin and warfarin: current and future advances.
    17. (1995). Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74:1–6.
    18. (2006). Biochemical and pharmacological profi les of YM150, an oral direct Factor Xa inhibitor. Blood, 108:Abstract 911.
    19. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fi brillation in the Atrial fi brillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W.): a randomised controlled trial.
    20. (2003). Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    21. (2003). Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement.
    22. (2007). Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
    23. (2007). Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fi brillation (PETRO Study.
    24. (2003). Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost,
    25. (2005). Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59–7939): an oral, direct Factor Xa inhibitor.
    26. (2004). Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement:
    27. (2006). Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban., an oral, direct Factor Xa inhibitor, in healthy subjects.
    28. (2001). Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost,
    29. (2007). Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    30. (2008). Effi cacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost.
    31. (2006). Emerging anticoagulants for the treatment of venous thromboembolism.
    32. (2008). Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    33. (2007). Factor Xa or thrombin: is factor Xa a better target?
    34. (2007). Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.
    35. (2001). Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, effi cacy, and safety.
    36. (1995). Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
    37. (2005). Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother,
    38. (2004). In vitro characteristics, anticoagulant effects and in vivo antithrombotic effi cacy of a novel, potent and orally active direct factor Xa inhibitor,
    39. (2004). Limitations of traditional anticoagulants.
    40. (2001). Managing oral anticoagulant therapy.
    41. (2004). Metabolism and distribution of [14C] BAY 59–7939 – an oral, direct Factor Xa inhibitor – in rat, dog and human. Drug Metab Rev,
    42. (2006). On behalf of the apixaban investigators. A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral Factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery.
    43. (2006). Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement.
    44. (2007). Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol
    45. (2004). Patients’ perspectives on taking warfarin: qualitative study in family practice.
    46. (2005). Pharmacokinetic profi le of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
    47. (2006). Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor.
    48. (2008). Prevention of venous thromboembolism: American College of Chest Physicians evidencebased clinical practice guidelines (8th Ed).
    49. (2005). Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fi brillation in clinic settings: a multi-site managed-care study. Ann Pharmacother,
    50. (2007). Rivaroxaban (BAY 19. – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen.
    51. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    52. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    53. (2007). Rivaroxaban-a novel, oral, direct Factor Xa inhibitor has no clinically relevant interaction with acetylsalicylic acid or naproxen.
    54. (2005). Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects.
    55. (2005). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther,
    56. (2003). Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    57. (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fi brillation (SPORTIF III.: randomised controlled trial.
    58. (2002). Structure-based design of novel potent nonpeptide thrombin inhibitors.
    59. (2001). The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res,
    60. (2003). The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    61. (2007). The effect of age and gender on the pharmacology and safety of the oral, direct Factor Xa inhibitor.
    62. (2007). The effi cacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    63. (2008). The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos,
    64. (2007). The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopaedic surgery.
    65. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    66. The RE-MOBILIZE Writing Committee 2008. The oral thrombin inhibitor dabigatran etexilate vs the north american enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery.
    67. (2007). The safety of warfarin therapy in the nursing home setting.
    68. (2006). Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells.
    69. (1999). Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C. Thromb Res,
    70. (2005). Thrombin stimulates proinfl ammatory and proliferative responses in primary cultures of human proximal tubule cells. Kidney Int,
    71. (2007). Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59–7939 in patients with acute symptomatic deep-vein thrombosis) study.
    72. (2003). What is all that thrombin for?
    73. (2005). Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    74. (2005). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fi brillation: a randomized trial.
    75. (2005). YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.